Men with advanced prostate cancer only have a 5-year survival rate of 28%, mainly due to resistance to therapy. Enolase-1 (ENO1), also known as α-enolase, is a glycolytic enzyme with promise as a target for treating neuroendocrine prostate cancer (NEPC) and an alternative to prostate-specific member antigen (PSMA) targeting.